Ventyx Biosciences, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -20.54. In total, the insiders bought 2 653 692 and sold 3 628 824 VTYX shares in the last 100 trades.

Insider Power

(Last 100 transactions)
-20.54
Buy 2 653 692 Shares
Sell 3 628 824 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 24, 2024 Common Stock Sell Nsv Partners Iii Lp 641 327
Jun 24, 2024 Common Stock Sell Subramaniam Somu 641 327
Jun 10, 2024 Common Stock Buy Mohan Raju 96 778
Jun 10, 2024 Stock Option (Right to Buy) Sell Mohan Raju 96 778
Jun 06, 2024 Stock Option (Right to Buy) Buy White William Richard 33 000
Jun 06, 2024 Stock Option (Right to Buy) Buy Cadoret-manier Onaiza 33 000
Jun 06, 2024 Stock Option (Right to Buy) Buy Gujrathi Sheila 33 000
Jun 06, 2024 Stock Option (Right to Buy) Buy Hulme Allison 33 000
Jun 06, 2024 Stock Option (Right to Buy) Buy Subramaniam Somu 33 000
May 16, 2024 Stock Option (Right to Buy) Buy Moore Matthew Richard 320 000
May 16, 2024 Buy Moore Matthew Richard 0
Apr 12, 2024 Common Stock Sell Subramaniam Somu 695 339
Apr 12, 2024 Common Stock Sell Nsv Partners Iii Lp 695 339
Apr 02, 2024 Common Stock Sell Krueger Christopher W 1 651
Apr 02, 2024 Common Stock Sell Nuss John 1 651
Apr 02, 2024 Common Stock Sell Mohan Raju 4 312
Apr 02, 2024 Common Stock Sell Auster Martin 1 405
Mar 28, 2024 Common Stock Buy Krueger Christopher W 4 531
Mar 28, 2024 Restricted Stock Units Sell Krueger Christopher W 4 531
Mar 28, 2024 Common Stock Buy Auster Martin 4 531
Mar 28, 2024 Restricted Stock Units Sell Auster Martin 4 531
Mar 28, 2024 Common Stock Buy Mohan Raju 11 843
Mar 28, 2024 Restricted Stock Units Sell Mohan Raju 11 843
Mar 28, 2024 Common Stock Buy Nuss John 4 531
Mar 28, 2024 Restricted Stock Units Sell Nuss John 4 531
Click to get the best stock tips daily for free!

About Ventyx Biosciences, Inc.

Ventyx Biosciences. Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002,... VTYX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT